An interventional study of Exercise Intervention in Lung Cancer, Non Small Cell Lung Cancer and Metastatic Lung Cancer, sponsored by Indiana University. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Indiana University · Not applicable, Interventional, and Supportive care
The purpose of this study is to examine how a multimodality (having or using a variety of methods to do something) exercise intervention may improve survival, function, and quality of life in participants with advanced lung cancer.
This study is a randomized control trial at a single institution comparing advanced lung cancer patients undergoing supervised home-based exercise program versus usual care. The intervention is a supervised home-based exercise program that will be coordinated by the MOVE program. The regimen will be 12 weeks in duration, three times a week, and administered by a trained professional virtually.
Participants will be randomized 1:1 to the exercise or usual care arm. Participants will be stratified on baseline frailty by the SPPB.
Primary Objective To compare changes patient-reported fatigue (by FACT-F survey) from baseline to post-intervention in patients with locally advanced and advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
Secondary Objectives
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 2 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.
Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patient is currently receiving maintenance immunotherapy for at least 1 month and planned for at least 3 additional months of therapy
Patient is willing and able to participate in a supervised home-based exercise program as determined by the MOVE program
a.Participants must have internet access and equipment to participate in virtual exercise
Exclusion Criteria:
Medical co-morbidities that preclude patient from participating in supervised exercise, including but not limited to:
Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands. All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session.
Behavioral: Exercise Intervention
Participants randomized to usual care arm will receive care per their treatment team. Usual care participants are encouraged to exercise but will not be provided components of the intervention. Participants in the usual care arm will be given usual care handouts at baseline.
Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands. All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session.
Change in patient-reported fatigue
Measured by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) survey
Time frame: baseline, week 12, and week 24
Change in cardiorespiratory fitness
Measured by VO2peak, estimated as time on the treadmill
Time frame: baseline, week 12, and week 24
Change in physical performance battery
total score on short physical performance battery
Time frame: baseline, week 12, and week 24
Change in muscle mass
measured by mg/kg2 on HU on CT scans
Time frame: baseline, and week 12
Change in muscle density
measured by mg/kg2 on HU on CT scans
Time frame: baseline, and week 12
Change in depression
measured by total score of HADS survey
Time frame: baseline, week 12, and week 24
Proportion of patients who are "fatigued"
measured by FACT-F score of \<43
Time frame: baseline, week 12, and week 24
Uptake of the study
the proportion of total patients approached, screened, and ultimately completing the baseline assessments
Time frame: date open to accrual until closed to accrual, up to 5 years
Adherence with the intervention defined
the proportion of scheduled sessions attended by participants randomized to the exercise intervention arm
Time frame: baseline to post 12-week intervention
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indiana University